ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael Wang, Frederick Lundry Locke, Javier Munoz, Andre Goy, Houston Eccleston Holmes, Tanya Siddiqi, Ian Flinn, Peter A McSweeney, Patrick Michael Reagan, Brian Thomas Hill, Caron A. Jacobson, David A. Rizzieri, Leonard T. Heffner, Samantha Mary Jaglowski, David Bernard Miklos, Paul Shaughnessy, Sherry Unabia, John M. Rossi, Yizhou Jiang, Rajul K. Jain
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Banner MD Anderson Cancer Center, Hackensack University Medical Center, City Of Hope National Medical Center, Sarah Cannon, Colorado Blood Cancer Institute, University of Rochester Medicine, Cleveland Clinic, Dana-Farber Cancer Institute, Duke Medical Center, Winship Cancer Institute, The Ohio State University, Stanford Medicine, Stanford University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889917976